Systematic Review on Fecal Calprotectin in Cystic Fibrosis

Overview

Journal J Pediatr (Rio J)

Specialty Pediatrics

Date 2022 May 6

PMID 35523321

Authors

Eduarda Sampaio Lazzarotto

Jannaina Ferreira de Melo Vasco

Fabiane Fuhr

Carlos Antonio Riedi

Nelson Augusto Rosario Filho

Affiliations

Soon will be listed here.

Abstract

Objectives: Fecal calprotectin is an inflammatory marker used for monitoring intestinal diseases. It has been studied as a marker of intestinal inflammation in cystic fibrosis (CF), a multi-systemic genetic disease caused by alterations to the CFTR gene. Manifestations of the disease favor a systemic inflammation not limited to the respiratory tract, therefore, calprotectin is a non-invasive and effective diagnostic method. The aim of the study was to perform a systematic review of the literature with a qualitative synthesis of studies.

Sources: The articles were selected from PubMed, Web of Science, Scielo and Lilacs.

Summary Of The Findings: Nine studies were selected for that qualitative synthesis, one was a randomized clinical trial, and eight were case-control or cohort designs. Most studies have indicated that calprotectin is a marker of systemic inflammation in CF and not just intestinal inflammation. Calprotectin is an aid in monitoring inflammatory bowel conditions in patients with cystic fibrosis.

Conclusion: Further studies should be conducted to investigate the role of this marker in the systemic inflammation of CF.

Citing Articles

The Role of Calprotectin in the Diagnosis and Treatment of Inflammatory Bowel Disease.

Wang W, Cao W, Zhang S, Chen D, Liu L Int J Mol Sci. 2025; 26(5).

PMID: 40076618 PMC: 11900593. DOI: 10.3390/ijms26051996.

Fecal calprotectin in pediatric gastrointestinal diseases: Pros and cons.

Al-Beltagi M, Saeed N, Bediwy A, Elbeltagi R World J Clin Pediatr. 2024; 13(2):93341.

PMID: 38948001 PMC: 11212754. DOI: 10.5409/wjcp.v13.i2.93341.

References

Wiecek S, Wos H, Kordys-Darmolinska B, Sankiewicz-Szkolka M, Grzybowska-Chlebowczyk U . The concentration of calprotectin in the stools of children with diagnosed cystic fibrosis. Prz Gastroenterol. 2017; 12(1):38-43. PMC: 5360654. DOI: 10.5114/pg.2016.58897. View

Schnapp Z, Hartman C, Livnat G, Shteinberg M, Elenberg Y . Decreased Fecal Calprotectin Levels in Cystic Fibrosis Patients After Antibiotic Treatment for Respiratory Exacerbation. J Pediatr Gastroenterol Nutr. 2019; 68(2):282-284. DOI: 10.1097/MPG.0000000000002197. View

Grad C, David L, Portincasa P, Dumitrascu D . Diagnostic value of calprotectin in irritable bowel syndrome and in inflammatory bowel disease. Rom J Intern Med. 2012; 50(1):3-6. View

Lee J, Leach S, Katz T, Day A, Jaffe A, Ooi C . Update of faecal markers of inflammation in children with cystic fibrosis. Mediators Inflamm. 2012; 2012:948367. PMC: 3439990. DOI: 10.1155/2012/948367. View

Manceau H, Chicha-Cattoir V, Puy H, Peoch K . Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin Chem Lab Med. 2016; 55(4):474-483. DOI: 10.1515/cclm-2016-0522. View

Ellemunter H, Engelhardt A, Schuller K, Steinkamp G . Fecal Calprotectin in Cystic Fibrosis and Its Relation to Disease Parameters: A Longitudinal Analysis for 12 Years. J Pediatr Gastroenterol Nutr. 2017; 65(4):438-442. DOI: 10.1097/MPG.0000000000001544. View

Rumman N, Sultan M, El-Chammas K, Goh V, Salzman N, Quintero D . Calprotectin in cystic fibrosis. BMC Pediatr. 2014; 14:133. PMC: 4048584. DOI: 10.1186/1471-2431-14-133. View

Lisowska A, Madry E, Pogorzelski A, Szydlowski J, Radzikowski A, Walkowiak J . Small intestine bacterial overgrowth does not correspond to intestinal inflammation in cystic fibrosis. Scand J Clin Lab Invest. 2010; 70(5):322-6. DOI: 10.3109/00365513.2010.486869. View

Kotze L, Nisihara R, Marion S, Cavassani M, Kotze P . FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. Arq Gastroenterol. 2015; 52(1):50-4. DOI: 10.1590/S0004-28032015000100011. View

10.

Ooi C, Syed S, Rossi L, Garg M, Needham B, Avolio J . Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation. Sci Rep. 2018; 8(1):17834. PMC: 6292911. DOI: 10.1038/s41598-018-36364-6. View

11.

Vaos G, Kostakis I, Zavras N, Chatzemichael A . The role of calprotectin in pediatric disease. Biomed Res Int. 2013; 2013:542363. PMC: 3794633. DOI: 10.1155/2013/542363. View

12.

Ooi C, Durie P . Cystic fibrosis from the gastroenterologist's perspective. Nat Rev Gastroenterol Hepatol. 2016; 13(3):175-85. DOI: 10.1038/nrgastro.2015.226. View

13.

Chaabouni T, Manceau H, Peoch K . Interest of fecal calprotectine dosage in inflammatory bowel diseases, state of the art and perspectives. Ann Biol Clin (Paris). 2016; 74(4):385-94. DOI: 10.1684/abc.2016.1172. View

14.

Garg M, Ooi C . The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy. Curr Gastroenterol Rep. 2017; 19(2):6. DOI: 10.1007/s11894-017-0546-0. View

15.

Koninckx C, Donat E, Benninga M, Broekaert I, Gottrand F, Kolho K . The Use of Fecal Calprotectin Testing in Paediatric Disorders: A Position Paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology Committee. J Pediatr Gastroenterol Nutr. 2021; 72(4):617-640. DOI: 10.1097/MPG.0000000000003046. View

16.

De Lisle R, Borowitz D . The cystic fibrosis intestine. Cold Spring Harb Perspect Med. 2013; 3(9):a009753. PMC: 3753720. DOI: 10.1101/cshperspect.a009753. View

17.

Enaud R, Hooks K, Barre A, Barnetche T, Hubert C, Massot M . Intestinal Inflammation in Children with Cystic Fibrosis Is Associated with Crohn's-Like Microbiota Disturbances. J Clin Med. 2019; 8(5). PMC: 6572243. DOI: 10.3390/jcm8050645. View

18.

Pathirana W, Chubb S, Gillett M, Vasikaran S . Faecal Calprotectin. Clin Biochem Rev. 2019; 39(3):77-90. PMC: 6370282. View

19.

Downey D, Martin S, Dempster M, Moore J, Keogan M, Starcher B . The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol. 2007; 42(3):216-20. DOI: 10.1002/ppul.20553. View

20.

Adriaanse M, van der Sande L, Van den Neucker A, Menheere P, Dompeling E, Buurman W . Evidence for a Cystic Fibrosis Enteropathy. PLoS One. 2015; 10(10):e0138062. PMC: 4617711. DOI: 10.1371/journal.pone.0138062. View